Home >> Research Area >>PI3K/Akt/mTOR Signaling>>PI3K>> VS-5584 (SB2343)

VS-5584 (SB2343)

MTOR/P13K inhibitor,potent and selective CAS# 1246560-33-7

VS-5584 (SB2343)

Catalog No. BCC2047----Order now to get a substantial discount!

Product Name & Size Price Stock
VS-5584 (SB2343): 5mg $104 In Stock
VS-5584 (SB2343): 10mg Please Inquire In Stock
VS-5584 (SB2343): 20mg Please Inquire Please Inquire
VS-5584 (SB2343): 50mg Please Inquire Please Inquire
VS-5584 (SB2343): 100mg Please Inquire Please Inquire
VS-5584 (SB2343): 200mg Please Inquire Please Inquire
VS-5584 (SB2343): 500mg Please Inquire Please Inquire
VS-5584 (SB2343): 1000mg Please Inquire Please Inquire
Related Products
  • IC-87114

    Catalog No.:BCC1161
    CAS No.:371242-69-2
  • PI-103

    Catalog No.:BCC1162
    CAS No.:371935-74-9
  • PIK-75

    Catalog No.:BCC1163
    CAS No.:372196-77-5
  • TGX-221

    Catalog No.:BCC1244
    CAS No.:663619-89-4
  • TG100-115

    Catalog No.:BCC1247
    CAS No.:677297-51-7
  • PIK-90

    Catalog No.:BCC1248
    CAS No.:677338-12-4

Quality Control of VS-5584 (SB2343)

Number of papers citing our products

Chemical structure

VS-5584 (SB2343)

3D structure

Chemical Properties of VS-5584 (SB2343)

Cas No. 1246560-33-7 SDF Download SDF
PubChem ID 46912230 Appearance Powder
Formula C17H22N8O M.Wt 354.41
Type of Compound N/A Storage Desiccate at -20°C
Synonyms SB2343
Solubility DMSO : 33.33 mg/mL (94.04 mM; Need ultrasonic)
Chemical Name 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine
SMILES CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N
Standard InChIKey QYBGBLQCOOISAR-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of VS-5584 (SB2343)

DescriptionVS-5584 (SB2343) is a potent and selective dual inhibitor of PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.
TargetsmTORPI3KαPI3Kα-H1047PI3KβPI3KδPI3Kγ
IC503.4 nM2.6 nM3.3 nM21 nM2.7 nM3.0 nM

Protocol

Cell Assay [1]
For proliferation assays in 96-well plates, SET-2, SNU-478, SNU-1196, SNU-245, SNU-1079, SNU-308, SNU-869, and MKN7 cells are used. The multiple myeloma cells (H929, MM1.S, MM1.R, R8226, U266) and nasopharyngeal cells (CNE-1, CNE-2, HONE1, HK1) are used. Cells are seeded at 30% to 50% confluency for adherent cells, or 2,000 to 6,000 cells for suspension cells and treated the following day with VS-5584 (in triplicates) at concentrations up to 10 μM for 48 hours. Cell viability is monitored using the CellTiter-Glo assay. Dose-response curves were plotted to determine IC50 values for the compounds using the XL-fit software[1].

Animal Administration [1]
Mice[1]Athymic BALB/c nude mice (BALB/cOlaHsd-Foxn1nu) are used. Fox-Chase severe combined immunodeficient (SCID) mice (CB17/Icr-Prkdcscid/CrlBltw) are used. Male (PC3 and COLO 205) or female (MV4-11 and HuH7) BALB/c nude mice or female SCID mice (NCI-N87) are implanted intradermally in the right flank with 5×106 (PC3, COLO205, HuH7, NCI-N87) or 1×107 (MV4-11) cells. Cells are resuspended in 70% (v/v; COLO205 and HuH7 only) or 50% (v/v) serum-free growth medium/Matrigel and injected in a total volume of 100 μL, using a 27.5-gauge needle. Dosing started 7 to 14 days after tumor implantation. VS-5584 (11 and 25 mg/kg) is dosed daily orally[1].

References:
[1]. Hart S, et al. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther, 2013, 12(2), 151-161.

VS-5584 (SB2343) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

VS-5584 (SB2343) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of VS-5584 (SB2343)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8216 mL 14.108 mL 28.2159 mL 56.4318 mL 70.5398 mL
5 mM 0.5643 mL 2.8216 mL 5.6432 mL 11.2864 mL 14.108 mL
10 mM 0.2822 mL 1.4108 mL 2.8216 mL 5.6432 mL 7.054 mL
50 mM 0.0564 mL 0.2822 mL 0.5643 mL 1.1286 mL 1.4108 mL
100 mM 0.0282 mL 0.1411 mL 0.2822 mL 0.5643 mL 0.7054 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on VS-5584 (SB2343)

VS-5584 (SB2343), a purine analog, is a novel small-molecule inhibitor of both mammalian target of rapamycin (mTOR) kinase and all class I phosphoinostide 3-kinase (PI3K) isoforms that ATP-competitively inhibits the activity of mTOR, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ with values of 50% inhibition concentration IC50 of 37 nmol/L, 16 nmol/L, 68 nmol/L, 25 nmol/L and 42 nmol/L respectively. VS-5585 robustly modulates the cellular PI3K/mTOR pathway, one of the most commonly activated signaling pathways in human cancer, through inhibition of phosphorylation of substrates downstream of PI3K and mTORC1/2. Moreover, VS-5584 has been found to dose-dependently inhibit PI3K/mTOR signaling in tumor tissue resulting in tumor growth inhibition in human xengograft models.

Reference

Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, Nagaraj H, Jayaraman R, Pasha KM, Ethirajulu K, Chng WJ, Mustafa N, Goh BC, Benes C, McDermott U, Garnett M, Dymock B, Wood JM. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. doi: 10.1158/1535-7163.MCT-12-0466. Epub 2012 Dec 27.

Featured Products
New Products
 

References on VS-5584 (SB2343)

Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.[Pubmed:25317974]

J Chem Inf Model. 2014 Nov 24;54(11):3238-50.

Phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR) act as critical effectors in a commonly deregulated cell signaling pathway in human cancers. The abnormal activation of the PI3K/mTOR pathway has been shown to play a role in initiation, progression, and metastasis of human tumors. Being one of the most frequently activated pathways in cancer, much effort has been directed toward inhibition of the PI3K/mTOR pathway as a novel oncology therapy. Previous work by a number of groups has revealed several selective PI3K and dual mTOR/PI3K inhibitors. However, there are few reports of therapeutic agents with a pan-PI3K/mTOR inhibitory profile within a narrow concentration range. We therefore initiated a drug discovery project with the aim of discovering dual mTOR/PI3K inhibitors which would equipotently inhibit the 4 isoforms of PI3K, alpha, beta, gamma, and delta, and mTOR a compelling profile for powerful blockage of the PI3K/mTOR pathway. A pharmacophore model was generated and used for designing a series of novel compounds, based on a purine scaffold, which potently inhibited mTOR and PI3Ks. These compounds contained a phenol headgroup essential for binding to the target proteins. Early efforts concentrated on finding replacements for the phenol as it was rapidly conjugated resulting in a short half-life in vivo. Compounds with a variety of headgroups were docked into the PI3Kalpha and mTOR ATP-binding sites, and aminopyrimidine and aminopyrazine were found to make excellent phenol replacements. Further structure guided optimization of side chains in the 8- and 9-positions of the purine resulted in potent inhibitors with good PKDM properties. As the PI3 kinases play a role in insulin signaling, it is believed that targeting mTOR selectively may give the benefit of blocking the AKT-pathway while avoiding the potential side effects associated with PI3K inhibition. As a result we designed a further series of selective mTOR kinase inhibitors. The project was successfully concluded by progressing both a dual mTOR/PI3K inhibitor, SB2343, and a selective mTOR inhibitor, SB2602, into preclinical development. SB2343 has since entered phase 1 clinical development as VS-5584.

Description

VS-5584 is a pan-PI3K/mTOR kinase inhibitor with IC50s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

Keywords:

VS-5584 (SB2343),1246560-33-7,SB2343,Natural Products,PI3K, buy VS-5584 (SB2343) , VS-5584 (SB2343) supplier , purchase VS-5584 (SB2343) , VS-5584 (SB2343) cost , VS-5584 (SB2343) manufacturer , order VS-5584 (SB2343) , high purity VS-5584 (SB2343)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: